BioVaxys Technology Corp. has announced its participation in the Emerging Growth Conference, inviting investors and analysts to attend a live presentation.
VANCOUVER, BC, January 14, 2025 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF), a clinical-stage company focused on developing a portfolio of vaccines using its novel DPX™ immune-educating platform, is scheduled to present at the Emerging Growth Conference on Thursday, January 16, 2025, from 3:25 PM to 3:35 PM Eastern Time. The company’s presentation will offer investors a real-time opportunity to interact with James Passin, CEO, and Kenneth Kovan, President & Chief Operating Officer.
Following the presentation, Passin and Kovan will answer questions from the audience. Investors can submit questions in advance to [email protected] or ask them during the event. BioVaxys management will attempt to address as many questions as possible.
To attend the conference and receive updates, investors are encouraged to register here: https://goto.webcasts.com/starthere.jsp?ei=1677199&tp_key=1991879e88&sti=bvaxf. An archived webcast will also be available on EmergingGrowth.com and the Emerging Growth YouTube Channel, http://www.YouTube.com/EmergingGrowthConference, after the event.
About the Emerging Growth Conference
The Emerging Growth Conference provides a platform for public companies to present their latest developments to the investment community. The conference focuses on companies in various growth sectors that demonstrate strong management teams, innovative products and services, and the potential for long-term growth. The audience includes thousands of individual and institutional investors, as well as investment advisors and analysts. Presentations are conducted via video webcasts.
About BioVaxys Technology Corp.
BioVaxys Technology Corp. (www.biovaxys.com) is a clinical-stage biopharmaceutical company committed to advancing patient care using novel immunotherapies based on its DPX™ immune-educating technology platform and its HapTenix© ‘neoantigen’ tumor cell construct platform. These platforms are being developed to treat cancers, infectious diseases, antigen desensitization for food allergies, and other immunological disorders. The DPX™ platform employs a proprietary mechanism to educate the immune system to generate a specific, strong, and enduring immune response.
BioVaxys’ clinical-stage pipeline includes maveropepimut-S (MVP-S), which is based on the DPX™ platform. MVP-S is in Phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum-resistant Ovarian Cancer. MVP-S uses antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers, and delivers an innate immune activator and a universal CD4 T cell helper peptide. The vaccine has demonstrated clinical benefit in multiple cancer indications, as well as the activation of a targeted and sustained, survivin-specific anti-tumor immune response.
BioVaxys is also developing DPX™+SurMAGE, a dual-targeted immunotherapy that combines antigenic peptides for both survivin and MAGE-A9 cancer proteins. The aim is to elicit immune responses to these two distinct cancer antigens simultaneously. Other products in development include DPX™-RSV for Respiratory Syncytial Virus, DPX+rPA for peanut allergy prophylaxis, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix© ‘neoantigen’ tumor cell construct platform. The latter is intended for refractive late-stage ovarian cancer.
BioVaxys common shares are listed on the CSE under the stock symbol ‘BIOV,’ trade on the Frankfurt Bourse (FRA: 5LB), and in the US (OTCQB: BVAXF).
For more information, visit www.biovaxys.com and connect with the company on X and LinkedIn.
ON BEHALF OF THE BOARDSigned
“James Passin”
James Passin, Chief Executive Officer
Phone: +1 740 358 0555
Cautionary Statements Regarding Forward-Looking Information
This press release contains forward-looking statements within the meaning of applicable Canadian and United States securities legislation, including the United States Private Securities Litigation Reform Act of 1995. These statements, other than statements of historical fact, relate to the future operating or financial performance of the Company. Forward-looking statements often use terms like “expects,” “anticipates,” “believes,” “intends,” “estimates,” “potential,” and similar expressions, or state that events, conditions, or results “will,” “may,” “could,” or “should” occur or be achieved. There is no guarantee that these statements will be accurate, and actual results and future events could differ materially. These forward-looking statements are based on beliefs, opinions, and projections as of the date of the statements. These statements are based on a number of estimates and assumptions, including the assumption that BioVaxys will be successful in developing and testing vaccines. These include significant uncertainties, and the risk that BioVaxys’ vaccines will not prove effective and/or will not receive the required regulatory approvals.
Regarding BioVaxys’ business, there are a number of risks that could impact product development. These include the need for more capital to back clinical trials, the company’s lack of operating history, the uncertainty of completing clinical trials and regulatory approval, and the uncertainty of the commercial viability of the products. Other risks include development costs and issues and obligations under license agreements, protecting intellectual property, and relying on third-party manufacturing. The Company does not assume any obligation to update any forward-looking statements unless required by law. Investors are encouraged to review BioVaxys’ continuous disclosure documents and audited annual consolidated financial statements available on SEDAR at www.sedar.com.
